期刊
ONCOIMMUNOLOGY
卷 1, 期 3, 页码 361-362出版社
LANDES BIOSCIENCE
DOI: 10.4161/onci.18482
关键词
dendritic cells; MyD88; CD40; tumor immunotherapy; inducible MyD88/CD40 (iMC)
To better control the licensing of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo within the context of an immunological synapse. This novel technology results in potent anti-cancer activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据